What is Leerink Partnrs' Estimate for ARWR FY2026 Earnings?

Key Points

• Leerink Partners has revised its earnings forecast for Arrowhead Pharmaceuticals, increasing the FY2026 estimate from ($1.66) to ($1.62) per share.
• The consensus estimate for Arrowhead's full-year earnings stands at ($2.42) per share, indicating potential improvements in future earnings.
• In its latest quarter, Arrowhead reported $2.75 EPS, significantly exceeding expectations and showing a positive trajectory in revenue growth.

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) - Equities research analysts at Leerink Partnrs raised their FY2026 earnings estimates for shares of Arrowhead Pharmaceuticals in a research report issued on Tuesday, August 5th. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology company will earn ($1.62) per share for the year, up from their prior forecast of ($1.66). The consensus estimate for Arrowhead Pharmaceuticals' current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Arrowhead Pharmaceuticals' FY2028 earnings at ($1.49) EPS.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.32). The firm had revenue of $27.77 million for the quarter, compared to the consensus estimate of $29.01 million. During the same period in the previous year, the business posted ($1.38) earnings per share.

ARWR has been the subject of a number of other reports. Chardan Capital restated a "buy" rating and issued a $60.00 price target on shares of Arrowhead Pharmaceuticals in a report on Monday. TD Cowen raised shares of Arrowhead Pharmaceuticals to a "strong-buy" rating in a research report on Monday, July 28th. Royal Bank Of Canada lowered their price objective on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday. HC Wainwright reaffirmed a "buy" rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 20th. Finally, Citigroup reduced their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating for the company in a research note on Tuesday, May 13th. Three equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $43.14.

Arrowhead Pharmaceuticals Trading Up 3.0%

Shares of ARWR stock traded up $0.50 during trading hours on Thursday, hitting $16.92. 1,197,746 shares of the company's stock traded hands, compared to its average volume of 1,886,577. Arrowhead Pharmaceuticals has a 12 month low of $9.57 and a 12 month high of $27.34. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.39. The stock's 50 day simple moving average is $16.48 and its 200 day simple moving average is $15.93. The stock has a market cap of $2.34 billion, a PE ratio of -13.24, a price-to-earnings-growth ratio of 23.70 and a beta of 0.94.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of institutional investors have recently made changes to their positions in ARWR. Vanguard Group Inc. raised its holdings in Arrowhead Pharmaceuticals by 8.4% during the 1st quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company's stock valued at $168,201,000 after buying an additional 1,018,273 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 25.0% during the 4th quarter. Avoro Capital Advisors LLC now owns 11,111,111 shares of the biotechnology company's stock valued at $208,889,000 after buying an additional 2,222,223 shares during the last quarter. Slate Path Capital LP raised its holdings in Arrowhead Pharmaceuticals by 7.1% during the 4th quarter. Slate Path Capital LP now owns 5,232,000 shares of the biotechnology company's stock valued at $98,362,000 after buying an additional 347,000 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in Arrowhead Pharmaceuticals by 138.0% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company's stock valued at $60,962,000 after buying an additional 2,774,933 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Arrowhead Pharmaceuticals by 1.0% during the 2nd quarter. Geode Capital Management LLC now owns 2,978,505 shares of the biotechnology company's stock valued at $47,067,000 after buying an additional 28,193 shares during the last quarter. Hedge funds and other institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.